https://www.selleckchem.com/products/mi-773-sar405838.html 057; 0.194]). This association was found only for NYHA functional class and depression-not for NT-proBNP and LVEF. Conclusions Experiencing depression and associated symptoms, such as lack of energy and fatigue, may lead to a further decrease of functional capacity, and consequently to a higher NYHA functional class in CHF patients. As NYHA functional class is associated with higher mortality, this may be a critical development for affected patients. Further studies are required to investigate whether or not this association could be an essential key that explains the pathway from depression to increased mortality in heart failure patients.As this investigative team aptly notes, uptake of hs-Tn in the US has lagged compared to the rest of the world. While reasons for this lie primarily with approval delays at the Food and Drug Administration (FDA), there remains a reluctance in many institutions to shift from conventional assays to their more sensitive counterparts. When pressed, decision makers at such facilities point to the absence of US data and feign uncertainty about potential accuracy in "their" patient populations. It is within this void that Peackock et al present new(ish) data on Beckman Coulter's high sensitivity troponin I (hsTnI) assay, showing that it can reliably identify emergency department (ED) patients with suspected acute coronary syndrome (ACS) who have not sustained myocardial injury. Such work is important from a validation perspective, though incremental at best, providing information that is really a mirror image of itself (i.e, absence of of a protein that reflects myocardial injury indicates absence of myocardial injury). Said another way, publication of data showing that the Beckman Coulter hsTnI assay can effectively rule out myocardial injury may be necessary to convince skeptics of its safety profile but the exercise is merely revealing an inherent truth based on known characte